Predictions
Incyte Corp.
Start price
Target price
Perf. (%)
€64.63
25.02.21
25.02.21
€70.00
3.84%
08.03.21
08.03.21
Could be worthwhile Investment >10% per year
Incyte Corp.
Start price
Target price
Perf. (%)
€67.64
24.02.21
24.02.21
-
24.02.22
24.02.22
-12.39%
25.11.21
25.11.21
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Dependend from some customers or products
Hologic Inc.
Start price
Target price
Perf. (%)
€62.50
24.02.21
24.02.21
-
24.02.22
24.02.22
1.60%
30.03.21
30.03.21
Probably not worthwhile Investment
Viracta Therapeutics Inc.
Start price
Target price
Perf. (%)
€15.09
23.02.21
23.02.21
-
23.02.22
23.02.22
18.33%
24.02.21
24.02.21
Innovative
Could be worthwhile Investment >10% per year
Good culture
No uniques
Astrazeneca ADR
Start price
Target price
Perf. (%)
€41.40
22.02.21
22.02.21
-
22.02.22
22.02.22
0.00%
10.03.21
10.03.21
Could be worthwhile Investment >10% per year
Medium risks for its business
Small cyclical dependencies
Celsion Corp.
Start price
Target price
Perf. (%)
€35.70
22.02.21
22.02.21
€60.00
22.02.22
22.02.22
-37.40%
06.03.21
06.03.21
Could be worthwhile Investment >10% per year
Good culture
Leading role in innovation
high free float
Teleflex Inc.
Start price
Target price
Perf. (%)
€320.00
21.02.21
21.02.21
-
21.02.22
21.02.22
14.38%
23.04.21
23.04.21
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Low dividend yield expected
Heidelberg Pharma AG
Start price
Target price
Perf. (%)
€8.98
21.02.21
21.02.21
€10.00
21.02.22
21.02.22
-54.90%
22.02.22
22.02.22
Market Leader or Top 3
Could be very worthwhile Investment >20% year
Known brand
Very Future proof/growth oriented business model
Vita 34 AG
Start price
Target price
Perf. (%)
€15.55
21.02.21
21.02.21
-
21.02.22
21.02.22
-25.08%
22.02.22
22.02.22
Very Future proof/growth oriented business model
Market Leader or Top 3
Could be very worthwhile Investment >20% year
Rising EBIT margin expected
Bio-Gate AG
Start price
Target price
Perf. (%)
€4.22
21.02.21
21.02.21
-
21.02.22
21.02.22
-5.21%
06.03.21
06.03.21
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Inovio Pharma
Start price
Target price
Perf. (%)
€11.30
20.02.21
20.02.21
€6.80
20.02.22
20.02.22
-38.75%
10.07.21
10.07.21
Very low/no dividend yield expected
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€23.36
20.02.21
20.02.21
€26.40
20.02.22
20.02.22
-34.73%
06.05.21
06.05.21
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Hexo Corp.
Start price
Target price
Perf. (%)
€93.80
19.02.21
19.02.21
€210.00
19.02.22
19.02.22
-66.72%
23.08.21
23.08.21
Could be worthwhile Investment >10% per year
Pixium Vision S.A.
Start price
Target price
Perf. (%)
€1.03
17.02.21
17.02.21
€3.00
17.02.22
17.02.22
-24.32%
25.12.21
25.12.21
Could be very worthwhile Investment >20% year
Leading role in innovation
Future proof or reliable business model
Nanorepro AG
Start price
Target price
Perf. (%)
€8.95
16.02.21
16.02.21
€5.00
16.02.22
16.02.22
-7.49%
18.10.21
18.10.21
Below average Management
Little innovation
Few uniques
Dependend from some customers or products
Perrigo Co. plc
Start price
Target price
Perf. (%)
€37.00
15.02.21
15.02.21
-
15.02.22
15.02.22
5.95%
11.07.21
11.07.21
Could be worthwhile Investment >10% per year
Undervalued
Higher risks for its business
Viatris Inc.
Start price
Target price
Perf. (%)
€15.40
15.02.21
15.02.21
€19.00
15.02.22
15.02.22
-14.92%
15.02.22
15.02.22
Undervalued
High dividend yield expected
Nanorepro AG
Start price
Target price
Perf. (%)
€8.60
15.02.21
15.02.21
€20.00
15.02.22
15.02.22
5.47%
23.09.21
23.09.21
Could be worthwhile Investment >10% per year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
